In Vivo CRO Market Size & Share 2024 to 2032

In Vivo CRO Market Size

In Vivo CRO Market size was valued at USD 4.7 billion in 2023 and is expected to exhibit growth of 7.8% from 2024 to 2032. One of the primary drivers is the increasing complexity of drug development process, that has led pharmaceutical and biotechnology companies to outsource these services to specialized CROs.

Additionally, the rising prevalence of chronic diseases and the need for innovative therapies have fueled the demand for in vivo studies, further fueling the market growth. Moreover, stringent regulations for drug approvals have increased the reliance on CROs for conducting preclinical in vivo studies to ensure compliance with regulatory standards. Furthermore, the growing trend of personalized medicine and the development of novel biologics and biosimilars have further propelled the demand for in vivo CRO services, driving market growth.
 

In vivo CRO services refer to the range of research services provided by Contract Research Organizations (CROs) that involve studies conducted on living organisms, typically animals, to assess the safety and efficacy of novel therapeutics. These services often include preclinical studies, such as toxicology, pharmacokinetics, and efficacy studies, conducted to support the development and regulatory approval of new drugs or medical products. In vivo CROs play a crucial role in drug development by providing expertise, facilities, and resources to conduct these studies in compliance with regulatory requirements.
 

In Vivo CRO Market Trends

• Increasing demand for personalized medicine is expected to drive the demand for in vivo CRO services.
   
• Personalized medicine requires a deep understanding of the patient's genetic makeup, lifestyle, and environment to develop targeted therapies. In vivo CRO services play a crucial role in this process by providing expertise in preclinical research, including animal studies to evaluate the safety and efficacy of new drugs and treatments.
   
• Additionally, personalized medicine often involves complex research methodologies, including genetically modified animal models and specialized disease models. Moreover, personalized therapies require rigorous testing and validation to meet regulatory standards. In vivo CROs with experience in navigating regulatory pathways and ensuring compliance are essential for advancing personalized medicine therapies.
   
• In 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Thus, as personalized medicine continues to advance, the need for specialized CRO services that can conduct complex in vivo studies is expected to increase, driving growth in the in vivo CRO industry.
   

In Vivo CRO Market Analysis

The market based on animal model is segmented into rodent-based and non-rodent-based animal models. The rodent-based segment is further segmented into rat models, mice models, and other rodent models. The rodent-based segment dominated the market in 2023 with a revenue of USD 3.8 billion.
 

• Rodents, especially mice and rats, are the most used animals in preclinical research due to their genetic, physiological, and anatomical similarities to humans. They are relatively easy to handle, breed quickly, and are cost-effective, making them ideal for large-scale studies.
   
• Additionally, their small size allows for housing in large numbers, facilitating statistical analysis and reducing variability.
   
• Moreover, the availability of well-characterized strains and genetically modified models further enhances their utility in studying various diseases and conditions.
   

Learn more about the key segments shaping this market

Download Free PDF

The in vivo CRO market based on service is classified into bioanalysis & DMPK studies, toxicity studies, biocompatibility testing, microbiological testing, and other services. The bioanalysis & DMPK studies segment dominated the market in 2023 with a market share of 40.6%.
 

• Bioanalysis & DMPK studies are crucial in drug development, providing critical information on how a drug is metabolized and distributed in the body, its pharmacological activity, and its potential toxicity. As regulatory agencies increasingly demand comprehensive data on these aspects, the need for bioanalysis & DMPK studies has grown significantly.
   
• Additionally, the complexity of new drug candidates, including biologics and gene therapies, further drives the demand for these services.
   

Based on drug type, the in vivo CRO market is classified into small molecule drugs and large molecule drugs. The small molecule drugs segment dominated the market and is expected to exhibit 7.9% CAGR between 2024 - 2032.
 

• Small molecule drugs offer advantages such as oral bioavailability, which enhances patient compliance, and well-established formulation techniques, leading to easier manufacturing processes.
   
• Additionally, these drugs often have a broader range of target diseases compared to biologics, making them attractive for pharmaceutical companies seeking to address a variety of medical conditions.
   
• Moreover, the robust pipeline of small molecule drugs in development further drives the demand for in vivo CRO services, as companies rely on these organizations for preclinical and clinical studies to assess the safety and efficacy of their compounds.
   

The in vivo CRO market based on therapeutic area is segmented into oncology, clinical pharmacology, cardiology, infectious diseases, neurology, gastroenterology & hepatology, metabolic & endocrine, ophthalmology, autoimmune / inflammatory conditions, and other therapeutic areas. The oncology segment is expected to reach USD 5.2 billion by 2032.
 

• The increasing incidence of cancer worldwide has led to a surge in research and development activities focused on oncology treatments. This has created a significant demand for in vivo CRO services specializing in oncology studies.
   
• Additionally, the complexity of oncology drug development, which often requires a combination of preclinical and clinical studies, drives pharmaceutical and biotechnology companies to outsource these tasks to specialized CROs.
   
• The oncology segment's high market share is further bolstered by the rising investments in oncology research, favorable government initiatives, and the growing trend of personalized medicine in cancer treatment, all of which contribute to the segment's strong growth trajectory within the market.
   

The in vivo CRO market based on end-use is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic & research institutes. The pharmaceutical & biopharmaceutical companies’ segment dominated the market in 2032 and is anticipated to grow at a CAGR of 8% over the forecast years.
 

• Pharmaceutical & biopharmaceutical companies rely heavily on CROs to conduct preclinical trials in animal models for their drug candidates, as outsourcing these services streamlines the drug development process and reduce costs.
   
• Furthermore, the increasing complexity of drug development, including the need for specialized expertise, genetically modified animal models, and technologies, has led these companies to seek partnerships with specialized CROs that provide in-vivo services.
   
• As a result, pharmaceutical and biopharmaceutical companies play a crucial role in driving the growth of market.
   

North America in vivo CRO market accounted for USD 2 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.6% between 2024 – 2032.
 

• The region's well-established pharmaceutical and biotechnology industries, coupled with a robust healthcare infrastructure and favorable regulatory environment, contribute to its dominance.
   
• Additionally, the presence of major market players and a strong emphasis on drug discovery and development, supported by significant investments in R&D by pharmaceutical and biotechnology companies further bolster the market.
   
• Moreover, the presence of a large patient population, particularly for chronic and lifestyle-related diseases, creates a robust demand for clinical trials and research services, thereby propelling the regional market growth.
   

In Vivo CRO Market Share

The in vivo CRO industry is characterized by the presence of several key players offering innovative services. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their service portfolios, and gain a competitive advantage.
 

In Vivo CRO Market Companies

Prominent players operating in the in vivo CRO industry include:

• Biocytogen
• Charles River Laboratories International Inc.
• Crown Bioscience
• Evotec SE
• GemPharmatech Co. Ltd.
• IQVIA Inc.
• Icon Plc
• Labcorp Drug Development
• Parexel International Corporation
• PsychoGenics Inc.
• Taconic Biosciences, Inc.
   

In Vivo CRO Industry News:

• In November 2023, Charles River Laboratories announced a strategic partnership with Aitia to advance drug development and in vivo oncology research. This joint effort combines Charles River's disease-relevant PDX data and expertise with Aitia's industry-leading digital twin technology to enhance drug discovery and development in the field of neurodegenerative diseases and oncology.
   
• In January 2023, Evotec SE entered into a partnership agreement with Janssen Biotech to develop targeted immune-based therapies for oncology. This helped the company to leverage its expertise in vivo services for drug discovery and development.
   

The in vivo CRO market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Animal Model

• Rodent-based
  • Rat models
  • Mice models
  • Other rodent models
• Non-rodent-based

Market, By Service

• Bioanalysis & DMPK studies
• Toxicity studies
  • GLP toxicology studies
  • Non-GLP toxicology studies
• Other services

Market, By Drug Type

• Small-molecule drugs
• Large-molecule drugs
  • Cell & gene therapy
  • RNA therapy
  • Other large molecule drugs

Market, By Therapeutic Area

• Oncology
• Clinical pharmacology
• Cardiology
• Infectious diseases
• Neurology
• Gastroenterology & hepatology
• Metabolic & endocrine
• Ophthalmology
• Autoimmune / inflammatory conditions
• Other therapeutic areas

Market, By End-use

• Pharmaceutical & biopharmaceutical companies
• Medical device companies
• Academic & research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa